The offer is subject to regulatory approval. The offer is expected to be completed late this year or early in 2015.

Nobel Biocare’s board of directors was advised by Goldman Sachs.

Mr. Stakebay says:

Danaher annual sales from the dental industry will approach $3 billion after the purchase, giving it an “unmatched position” in dental implants as Nobel Biocare will expand the company’s presence in the premium segment of the market.